Search
ivosidenib (Tibsovo)
Indications:
- relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation
Dosage:
- 500 mg QD
Adverse effects:
- low frequency of serious adverse effects
Laboratory:
- IDH1 gene mutation
Mechanism of action:
- inhibits mutant IDH1
- transfusion independence, durable remissions
Related
vorasidenib (Servier)
General
enzyme inhibitor
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM correlations
References
- Ingram I.
Ivosidenib Induces Deep Remissions in IDH1-Mutant AML
On strength of phase I data, drug appears headed for
FDA approval.
MedPage Today. June 03, 2018
https://www.medpagetoday.com/meetingcoverage/asco/73242
- DiNardo CD, Stein EM, de Botton S et al
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or
Refractory AML.
N Engl J Med. Jun 2, 2018
PMID: 29860938
https://www.nejm.org/doi/full/10.1056/NEJMoa1716984
- Pollyea DA, et al
Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory
acute myeloid leukemia (R/R AML): Results of a phase 1 study.
American Society of Clinical Oncology (ASCO) 2018;
Abstract 7000
- HIGHLIGHTS OF PRESCRIBING INFO
TIBSOVO (ivosidenib tablets), for oral use
https://www.tibsovopro.com/pdf/prescribinginformation.pdf